134 related articles for article (PubMed ID: 2719737)
21. Biocommodity Engineering.
Lynd LR; Wyman CE; Gerngross TU
Biotechnol Prog; 1999 Oct; 15(5):777-793. PubMed ID: 10514248
[TBL] [Abstract][Full Text] [Related]
22. Mass spectrometric methodologies for the analysis of biotechnologically produced protein pharmaceuticals.
Malorni A
Farmaco; 1992 May; 47(5 Suppl):723-40. PubMed ID: 1524622
[TBL] [Abstract][Full Text] [Related]
23. Process Analytical Technology (PAT): batch-to-batch reproducibility of fermentation processes by robust process operational design and control.
Gnoth S; Jenzsch M; Simutis R; Lübbert A
J Biotechnol; 2007 Oct; 132(2):180-6. PubMed ID: 17559961
[TBL] [Abstract][Full Text] [Related]
24. Process validation for cell culture-derived pharmaceutical proteins.
Lubiniecki AS; Wiebe ME; Builder SE
Bioprocess Technol; 1990; 10():515-41. PubMed ID: 1367070
[TBL] [Abstract][Full Text] [Related]
25. Validation of fermentation processes.
Lubiniecki AS; Gardner AR; Smith TM; Wang WK; McAllister PR; Federici MM
Dev Biol (Basel); 2003; 113():37-44; discussion 111-2. PubMed ID: 14620850
[TBL] [Abstract][Full Text] [Related]
26. The preparation and validation of stock cultures of mammalian cells.
Facklam TJ; Geyer S
Bioprocess Technol; 1991; 13():54-85. PubMed ID: 1367151
[TBL] [Abstract][Full Text] [Related]
27. The control of biological medicinal products produced by recombinant DNA technology.
Griffiths E
Dev Biol Stand; 1985; 59():155-9. PubMed ID: 4007273
[TBL] [Abstract][Full Text] [Related]
28. Ensuring the consistency of rDNA-derived biologicals: the contribution of gene sequencing.
Griffiths E
Dev Biol Stand; 1994; 83():179-82. PubMed ID: 7883093
[TBL] [Abstract][Full Text] [Related]
29. Stability testing requirements for vaccines--draft guidelines of the International Conference on Harmonization.
Haase M
Dev Biol Stand; 1996; 87():309-18. PubMed ID: 8854031
[TBL] [Abstract][Full Text] [Related]
30. Upflow anaerobic sludge blanket reactor--a review.
Bal AS; Dhagat NN
Indian J Environ Health; 2001 Apr; 43(2):1-82. PubMed ID: 12397675
[TBL] [Abstract][Full Text] [Related]
31. Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies.
Hartman TE; Sar N; Genereux K; Barritt DS; He Y; Burky JE; Wesson MC; Tso JY; Tsurushita N; Zhou W; Sauer PW
Biotechnol Bioeng; 2007 Feb; 96(2):294-306. PubMed ID: 16897745
[TBL] [Abstract][Full Text] [Related]
32. [Studies on quality and safety control of drugs for human use from transgenic animals/clone animals].
Hayakawa T; Toyoshima S; Yamaguchi T; Kawanishi T
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2001; (119):1-26. PubMed ID: 11915277
[TBL] [Abstract][Full Text] [Related]
33. Microarray-based gene expression analysis as a process characterization tool to establish comparability of complex biological products: scale-up of a whole-cell immunotherapy product.
Wang M; Senger RS; Paredes C; Banik GG; Lin A; Papoutsakis ET
Biotechnol Bioeng; 2009 Nov; 104(4):796-808. PubMed ID: 19591186
[TBL] [Abstract][Full Text] [Related]
34. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
35. Influence of the cellular host-vector system on the quality of therapeutic proteins obtained by recombinant DNA technology.
Cassani G
Arzneimittelforschung; 1988 May; 38(5):762-4. PubMed ID: 3415722
[TBL] [Abstract][Full Text] [Related]
36. Development of a fed-batch fermentation process to overproduce phosphoenolpyruvate carboxykinase using an expression vector with promoter and plasmid copy number controllable by heat.
Chao YP; Chern JT; Lin WS; Wang ZW
Biotechnol Bioeng; 2003 Nov; 84(4):459-66. PubMed ID: 14574704
[TBL] [Abstract][Full Text] [Related]
37. Genetic stability and recombinant product consistency.
Burstyn D; Copmann T; Dinowitz M; Garnick R; Losikoff A; Lubiniecki A; Wiebe M
Biologicals; 1993 Jun; 21(2):147-9. PubMed ID: 8297595
[TBL] [Abstract][Full Text] [Related]
38. Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris.
Faber BW; Remarque EJ; Kocken CH; Cheront P; Cingolani D; Xhonneux F; Jurado M; Haumont M; Jepsen S; Leroy O; Thomas AW
Vaccine; 2008 Nov; 26(48):6143-50. PubMed ID: 18804135
[TBL] [Abstract][Full Text] [Related]
39. Process and product monitoring of recombinant DNA-derived biopharmaceuticals with high-performance capillary electrophoresis.
Sunday BR; Sydor W; Guariglia LM; Obara J; Mengisen R
J Capill Electrophor Microchip Technol; 2003; 8(5-6):87-99. PubMed ID: 15369173
[TBL] [Abstract][Full Text] [Related]
40. Human chymotrypsinogen B production with Pichia pastoris by integrated development of fermentation and downstream processing. Part 1. Fermentation.
Curvers S; Brixius P; Klauser T; Thömmes J; Weuster-Botz D; Takors R; Wandrey C
Biotechnol Prog; 2001; 17(3):495-502. PubMed ID: 11386871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
